Company Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006.
AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jan 26, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 117 |
| CEO | Daniel R. Faga |
Contact Details
Address: 10770 Wateridge Circle, Suite 210 San Diego, California 92121 United States | |
| Phone | 858-362-6295 |
| Website | anaptysbio.com |
Stock Details
| Ticker Symbol | ANAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001370053 |
| CUSIP Number | 032724106 |
| ISIN Number | US0327241065 |
| Employer ID | 20-3828755 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Faga | President, Chief Executive Officer and Director |
| Eric J. Loumeau | Chief Legal Officer |
| Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. | Chief Medical Officer |
| Dennis M. Mulroy | Chief Financial Officer |
| Beth Mueller | Senior Vice President of Human Resources |
| Dr. Martin Dahl Ph.D. | Senior Vice President of Research |
| Benjamin Stone | Chief Business Officer |
| Douglas A. Rich M.B.A. | Senior Vice President of CMC |
| Monique Da Silva | Senior Vice President of Corporate Affairs |
| Priya Raina | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 144 | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 30, 2024 | 144 | Filing |
| Jan 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |